Australian anti-cancer drug picked as one of the world’s top 10 most promising new drug products in 2011
Immune System Therapeutics (IST) announced its lead anti-cancer product, MDX-1097, had been recognized as one of Windhover's Top 10 most promising new drug products for 2011. Windhover is a provider of business information to the pharmaceutical, biotechnology, and medical device industries. MDX-1097 is IST’s lead anti-cancer candidate for the treatment of deadly multiple myeloma blood cancer. IST’s drug MDX-1097 was chosen using a variety of criteria, including mechanism of action, initial marketable indication , potential for follow-on indications and its potential for licensing.
"We are excited with the promise MDX-1097 has demonstrated to date in patients with multiple myeloma, and pleased that industry experts have recognized the potential of this new drug candidate to attract partners to accelerate its development," said IST Chief Executive Officer Dr Calum McKinlay.
In June 2011, MDX-1097 received orphan drug designation from US health regulators, giving the company and its potential licensing partners help with the regulatory approval process and marketing exclusivity in the US for a number of years. IST also recently announced the expansion of its Phase IIa clinical trial in Australia following encouraging responses from the first dosed patients and positive safety data.
Other news from the department business & finance
